Goldline Pharma IPO Sees Record-Setting Subscription Demand, Exceeding 782 Times, Amidst Anticipation for GMP, Allotment, and Listing Dates
Goldline Pharmaceutical
IPOGoldline Pharmaceutical Records Highest Subscription in SME Segment this Year
Goldline Pharmaceutical, a Nagpur-based pharmaceutical products marketing company, has witnessed a robust demand for its initial public offering (IPO), with the public issue recording a massive 781.85 times subscription on May 14, the final day of bidding. This marked the second-highest subscription in the SME segment in the current calendar year after Gabion Technologies India IPO, which was booked more than 800 times in January 2026.
The company is raising Rs 11.61 crore via an initial public offering (IPO) of 27 lakh shares, with a price band of Rs 41-43 per share. Investors have bid 153.86 crore equity shares against the offer size of 19.68 lakh shares, via 1.66 lakh applications. The breakdown ofsubscriptions is as follows:
| Investor Category | Subscription Times | Allotted Quota |
|---|---|---|
| Non-institutional Investors | 1,227.90 | |
| Retail Investors | 881.15 | |
| Qualified Institutional Buyers | 180.22 |
Non-institutional investors took the lead in terms of support, bidding 1,227.90 times their allotted quota. The portions set aside for retail investors and qualified institutional buyers were subscribed 881.15 times and 180.22 times, respectively.
The IPO share allotment will be finalised by May 15, while Goldline Pharmaceutical shares will be available for trading on the BSE SME on May 19. Market observers note that Goldline IPO shares traded at around 35% premium in the grey market.
Goldline Pharmaceutical intends to utilise Rs 8.35 crore of IPO proceeds for repayment of certain outstanding borrowings, and the remaining amount for general corporate purposes. As of March 2026, the company's total borrowings amounted to Rs 9.1 crore.
Goldline Pharmaceutical is engaged in marketing of pharmaceutical products under the brand Goldline. The company does not manufacture any pharma products, instead, it entered into contractual arrangements with third-party manufacturers. Presently, it has contractual arrangements with 15 manufacturers and 8 distributors. Cumulative Capital acted as the merchant banker for the Goldline Pharmaceutical IPO.
Read also: SMR Jewels IPO Successfully Lists with Institutional Support
Investor Takeaway
Investors should be cautious of the high subscription demand and potential listing volatility.
More in IPO
SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire
SMR Jewels IPO Successfully Lists with Institutional Support
Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO
